- Home
- AMN vs AUPH Comparison
AMN vs AUPH Comparison
Compare AMN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMN
- AUPH
- Stock Information
- Founded
- AMN 1985
- AUPH 1993
- Country
- AMN United States
- AUPH Canada
- Employees
- AMN N/A
- AUPH N/A
- Industry
- AMN Assisted Living Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- AMN Health Care
- AUPH Health Care
- Exchange
- AMN Nasdaq
- AUPH Nasdaq
- Market Cap
- AMN 1.0B
- AUPH 999.8M
- IPO Year
- AMN 2001
- AUPH 1999
- Fundamental
- Price
- AMN $18.49
- AUPH $7.75
- Analyst Decision
- AMN Hold
- AUPH Strong Buy
- Analyst Count
- AMN 8
- AUPH 2
- Target Price
- AMN $38.50
- AUPH $11.50
- AVG Volume (30 Days)
- AMN 871.6K
- AUPH 1.3M
- Earning Date
- AMN 05-08-2025
- AUPH 05-01-2025
- Dividend Yield
- AMN N/A
- AUPH N/A
- EPS Growth
- AMN N/A
- AUPH N/A
- EPS
- AMN N/A
- AUPH 0.04
- Revenue
- AMN $2,983,781,000.00
- AUPH $235,133,000.00
- Revenue This Year
- AMN N/A
- AUPH $11.86
- Revenue Next Year
- AMN $3.63
- AUPH $24.96
- P/E Ratio
- AMN N/A
- AUPH $193.75
- Revenue Growth
- AMN N/A
- AUPH 33.97
- 52 Week Low
- AMN $18.15
- AUPH $4.71
- 52 Week High
- AMN $70.07
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- AMN 31.81
- AUPH 46.63
- Support Level
- AMN $18.15
- AUPH $7.59
- Resistance Level
- AMN $19.97
- AUPH $7.83
- Average True Range (ATR)
- AMN 1.26
- AUPH 0.35
- MACD
- AMN -0.26
- AUPH -0.02
- Stochastic Oscillator
- AMN 8.92
- AUPH 65.84
About AMN AMN Healthcare Services Inc
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are; nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. A majority of its revenue is generated from the nurse and allied solutions segment which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.